|
|
|
|
 |
3rd
Generation PSA
***OUR LABORATORY IS NOW OFFERING A NEW TEST***
- The 3rd Generation PSA Assay
- "PSA-positive tumors showed improved disease-free and overall survival over women with PSA-negative tumors"
- THIS NEW ULTRASENSITIVE METHOD HAS THE LOWEST MARGIN OF ERROR DUE TO ITS EXTREMELY HIGH SENSITIVITY, PROVIDING HIGHER ACCURACY THAN IS COMMERCIALLY AVAILABLE.
- The 3rd Generation PSA test, because of its extremely high sensitivity, detects levels of PSA in postradical prostatectomy patients. However, nonprostatic PSA can be found in female sera that may be of great importance in breast, ovarian, and other tumors.
- Recent clinical research has further confirmed the role of PSA in the management of various nonprostatic cancers, most significantly breast tumors.
- Immunofluorometric studies were conducted to analyze serum samples from postradical prostatectomy and breast cancer patients. As a result, very low PSA levels were found in postradical prostatectomy patients, especially by the utilization of the 3rd Generation PSA test. The exceptionally high sensitivity of the test, used by American Metabolic Laboratories, 0.003 ng/mL, allows earlier detection of PSA after prostatectomy.
- Women with breast cancer demonstrated a favorable prognosis when PSA was present in tumor cystol, i.e. PSA-positive tumors showed improved disease-free and overall survival over women with PSA-negative tumors. It has been reported also that PSA levels in nipple aspirate were inversely correlated with breast cancer risk.
- Specimen Requirements : 200 - 500 µL serum or aspirate
- CPT code : 84153
- Price : $64.00
- Thank you for your attention and support,
- E.K. Schandl, M.S., Ph.D., FACB, SC (ASCP), CC
(NRCC), LNC Clinical Laboratory Director (Practicing Laboratory Medicine
in the Hollywood, Florida area for the past 22 years.)